Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Three Distraction Techniques for Pain and Anxiety in Children During Allergy Skin Prick Testing

26 de agosto de 2026 actualizado por: Leyla Erdim, Istanbul University

The Effect of Three Different Distraction Techniques on Anxiety and Pain Levels in Children During Allergy Skin Prick Testing: A Randomized Controlled Trial

This randomized controlled trial compared three distraction techniques-animated cartoons, DistrACTION® Cards, and interactive video games-with standard care for reducing procedural pain and anxiety in children aged 6-10 years undergoing allergy skin prick testing. A total of 161 children were randomly assigned to four groups. Pain was rated by the child, a parent, and the researcher with the Wong-Baker FACES Pain Rating Scale during and after the procedure, and anxiety was rated by the parent and the researcher with the Children's Fear Scale before, during, and after the procedure.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

This single-center, four-arm, parallel-group randomized controlled trial was conducted in the pediatric allergy outpatient clinic of a training and research hospital in Istanbul, Turkey, between November 2019 and January 2020. Children aged 6-10 years referred for allergy skin prick testing were randomly allocated by computer-generated assignment to a cartoon group (n = 40), a DistrACTION® Cards group (n = 40), a video game group (n = 40), or a standard-care control group (n = 41). All tests were performed by the same pediatric nurse under identical conditions. Between-group differences were tested with one-way ANOVA and change over time with two-way repeated-measures ANOVA.

Tipo de estudio

Intervencionista

Inscripción (Actual)

161

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Istanbul, Turquía (Türkiye)
        • Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Aged 6-10 years
  • Referred for allergy skin prick testing
  • Consent of both child and parent
  • No analgesic use in the previous six hours
  • Able to understand the Wong-Baker FACES Pain Rating Scale and answer the card questions

Exclusion Criteria:

  • Neurodevelopmental conditions (diagnosis of autism or intellectual disability)
  • Chronic mental, cognitive, or visual problems
  • Cognitive, visual, or hearing impairment preventing scale use

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Cartoon group (CG)
Children watched a self-selected, age-appropriate animated cartoon on a tablet computer during the skin prick test.
Children watched a self-selected, age-appropriate animated cartoon on a tablet computer during the skin prick test.
Experimental: DistrACTION® Cards group (DC)
Children viewed DistrACTION® Cards and answered goal-directed visual-search questions asked by the researcher during the skin prick test.
Children viewed DistrACTION® Cards and answered goal-directed visual-search questions asked by the researcher during the skin prick test.
Experimental: Video game group (VG)
Children played a self-selected interactive video game on a tablet with the non-tested arm during the skin prick test.
Children played a self-selected interactive video game on a tablet with the non-tested arm during the skin prick test.
Sin intervención: Control group (C)
Children received the clinic's standard protocol; the nurse explained and performed the test, and no additional distraction was provided.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Child-reported procedural pain
Periodo de tiempo: During the skin prick test, a procedure lasting approximately 3 minutes
Pain self-reported by the child on the Wong-Baker FACES Pain Rating Scale (0 = no pain to 10 = worst possible pain; higher scores indicate more pain).
During the skin prick test, a procedure lasting approximately 3 minutes

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Child-reported pain after the procedure
Periodo de tiempo: Immediately after the skin prick test, up to 15 minutes after the procedure
Pain self-reported by the child on the Wong-Baker FACES Pain Rating Scale (0 = no pain to 10 = worst possible pain; higher scores indicate more pain).
Immediately after the skin prick test, up to 15 minutes after the procedure
Parent-reported pain
Periodo de tiempo: During the skin prick test (approximately 3 minutes) and immediately after the procedure (up to 15 minutes)
Pain reported by the parent on the Wong-Baker FACES Pain Rating Scale (0 = no pain to 10 = worst possible pain; higher scores indicate more pain).
During the skin prick test (approximately 3 minutes) and immediately after the procedure (up to 15 minutes)
Researcher-reported pain
Periodo de tiempo: During the skin prick test (approximately 3 minutes) and immediately after the procedure (up to 15 minutes)
Pain reported by the researcher on the Wong-Baker FACES Pain Rating Scale (0 = no pain to 10 = worst possible pain; higher scores indicate more pain).
During the skin prick test (approximately 3 minutes) and immediately after the procedure (up to 15 minutes)
Parent-reported anxiety
Periodo de tiempo: Approximately 10 minutes before the skin prick test, during the test (approximately 3 minutes), and immediately after the procedure (up to 15 minutes)
Anxiety reported by the parent using the Children's Fear Scale (0 = no anxiety to 4 = severe anxiety; higher scores indicate higher anxiety).
Approximately 10 minutes before the skin prick test, during the test (approximately 3 minutes), and immediately after the procedure (up to 15 minutes)
Researcher-reported anxiety
Periodo de tiempo: Approximately 10 minutes before the skin prick test, during the test (approximately 3 minutes), and immediately after the procedure (up to 15 minutes)
Anxiety reported by the researcher using the Children's Fear Scale (0 = no anxiety to 4 = severe anxiety; higher scores indicate higher anxiety).
Approximately 10 minutes before the skin prick test, during the test (approximately 3 minutes), and immediately after the procedure (up to 15 minutes)
Interrater agreement
Periodo de tiempo: During the skin prick test (approximately 3 minutes) and immediately after the procedure (up to 15 minutes)
Intraclass correlation coefficient between child, parent, and researcher ratings.
During the skin prick test (approximately 3 minutes) and immediately after the procedure (up to 15 minutes)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Leyla Erdim, Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

7 de noviembre de 2019

Finalización primaria (Actual)

12 de enero de 2020

Finalización del estudio (Actual)

21 de enero de 2020

Fechas de registro del estudio

Enviado por primera vez

24 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

26 de agosto de 2026

Publicado por primera vez (Actual)

31 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

31 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

26 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2019-19-01

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data will not be shared.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .